The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
Official Title: A Randomized, Open-label Phase III Clinical Trial Comparing Antivascular Therapy Combined With Standard Chemotherapy and Standard Chemotherapy in Adjuvant Therapy for Patients With Triple-Negative Breast Cancer, Basal-like Immunosuppressed Subtype (BCTOP-T-A03)
Study ID: NCT05909332
Brief Summary: This is a randomized, open-label phase III clinical trial comparing antivascular therapy combined with standard chemotherapy and standard chemotherapy in adjuvant therapy for patients with triple-negative breast cancer, basal-like/Immune suppressed subtype.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Beijing Cancer Hospital, Beijing, Beijing, China
Chongqing Cancer Hospital, Chongqing, Chongqing, China
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Guangdong Academy of Medical Sciences Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center, Guangdong, Guangzhou, China
Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China
The First Hospital of China Medical University, Shenyang, Liaoning, China
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, Shanghai, China
Shanghai First Maternity and Infant Hospital, Shanghai, Shanghai, China
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China